Amplia CEO and MD Chris Burns spoke with Bulls ‘n Bears host, Matt Birney, this week to discuss the Company’s progress on ACCENT trial investigating FAK-inhibitor narmafotinib (AMP945) in pancreatic cancer.
Dr. Burns shared positive early results from the Phase 2a trial, which initially enrolled 26 patients:
“It’s early days, but we’ve already seen 6 patients show a significant reduction in their tumour size, and we’ve had another 6 patients show stable disease over time. It’s a developing data set, but we’re already pretty excited about that data, and we can now recruit a further 24 patients in the trial.”
Have a listen:
